Loading
Gedeptin is a gene therapy from GeoVax that is injected into a tumour and makes the tumour turn a follow-up drug into a poison for itself. It has been tested in advanced head and neck cancer.
Gedeptin is GeoVax's gene-directed enzyme prodrug therapy, licensed from PNP Therapeutics in 2021 and developed with National Cancer Institute funding. A cycle consists of intratumoral injections followed by fludarabine phosphate. GeoVax reports a phase 1 dose-ranging study and a completed phase 1b/2a trial (PNP-002, NCT03754933) of repeat cycles in advanced head and neck squamous cell carcinoma with injectable tumours and no curative option, and an FDA orphan drug designation for intratumoral treatment of anatomically accessible oral and pharyngeal cancers. A phase 2 trial with an immune checkpoint inhibitor as first-line treatment before curative surgery is planned for the second half of 2027.
A replication-deficient adenovirus vector, injected into the tumour, transduces tumour cells with a non-human gene whose enzyme converts the inactive prodrug fludarabine phosphate, given afterwards, into an active anti-tumour compound in the tumour, as described by GeoVax.
1.Gedeptin slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Gedeptin" OR ABSTRACT:"Gedeptin" OR TITLE:"Gedeptin GDEPT, adenovirus PNP with fludarabine phosphate" OR ABSTRACT:"Gedeptin GDEPT, adenovirus PNP with fludarabine phosphate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gedeptin, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/